International Clinical Trial: A Study to Investigate the Safety, Reactogenicity, and Immunogenicity of mRNA-1469 Vaccine to Prevent Ebola-Bundibugyo Virus Disease in Healthy Adult Participants

Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07737717) titled 'A Study to Investigate the Safety, Reactogenicity, and Immunogenicity of mRNA-1469 Vaccine to Prevent Ebola-Bundibugyo Virus Disease in Healthy Adult Participants' on July 27.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Prevention. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).

Primary Sponsor: ModernaTX, Inc.

Condition: Ebola-Bundibugyo Virus Disease (Ebola-BDBV)

Intervention: Biological: mRNA-1469

Recruitment Status: Not recruiting

Phase: Phase 1

Date of First Enrollment: July 31, 2026

Tar...